Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis

BACKGROUND: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive disease that makes up about 20% of all invasive breast cancers. HER2+ breast cancer is associated with poor prognosis and high mortality rates, but the development of HER2-targeted therapies, such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Florence R., Coombes, Megan E., Wylie, Quinlan, Yurchenko, Mariya, Brezden-Masley, Christine, Hutton, Brian, Skidmore, Becky, Cameron, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634826/
https://www.ncbi.nlm.nih.gov/pubmed/29017563
http://dx.doi.org/10.1186/s13643-017-0588-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634826/
https://www.ncbi.nlm.nih.gov/pubmed/29017563
http://dx.doi.org/10.1186/s13643-017-0588-2

Ejemplares similares